| abstract |
The invention provides compounds of the formula I wherein R1, R2, R3, R4 are as defined and their pharmaceutically acceptable salts. The compounds of formula 1 are indicated to have activity to inhibit cdk5, cdk2 and GSK-3. It provides pharmaceutical compositions and methods comprising compounds of the formula 1 for treating and preventing diseases and conditions that involve abnormal cell growth, such as cancer, neurodegenerative diseases and conditions and those affected by the neurotransmission of dopamine. Pharmaceutical compositions and methods comprising compounds of formula 1 for treating male fertility and sperm motility, diabetes mellitus, impaired glucose tolerance, metabolic syndrome or syndrome X are also described; polycystic ovarian syndrome, adipogenesis and obesity; myogenesis and fragility, for example the deterioration of physical characteristics related to com. age ; acute sarcopenia, for example muscular atrophy and / or cachexia associated with burns, bed rest, limb immobilization or major thoracic, abdominal, and / or orthopedic surgery; sepsis; hair loss, rare and baldness; and immunodeficiency. |